English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Doxorubicin (DOX)-based chemotherapy for Hodgkin lymphoma (HL) yields excellent disease-free survival, but poses a substantial risk of subsequent left ventricular (LV) dysfunction and heart failure, typically with delayed onset. At the cellular level, this cardiotoxicity includes deranged cardiac glucose metabolism.    Methods  By reviewing the hospital records from January 2008 through December 2016, we selected HL patients meeting the following criteria: ≥ 18 year-old; first-line DOX-containing chemotherapy; no diabetes and apparent cardiovascular disease; 18-fluoro-deoxyglucose positron emission tomography ( 18 FDG-PET) scans before treatment (PET STAGING ), after 2 cycles (PET INTERIM ) and at the end of treatment (PET EOT ); at least one echocardiography ≥ 6 months after chemotherapy completion (ECHO POST ). We then evaluated the changes in LV  18 FDG standardized uptake values (SUV) during the course of DOX therapy, and the relationship between LV-SUV and LV ejection fraction (LVEF), as calculated from the LV diameters in the echocardiography reports with the Teicholz formula.    Results  Forty-three patients (35 ± 13 year-old, 58% males) were included in the study, with 26 (60%) also having a baseline echocardiography available (ECHO PRE ). LV-SUV gradually increased from PET STAGING  (log-transformed mean 0.20 ± 0.27) to PET INTERIM  (0.27 ± 0.35) to PET EOT  (0.30 ± 0.41;  P  for trend < 0.001). ECHO POST  was performed 22 ± 17 months after DOX chemotherapy. Mean LVEF was normal (68.8 ± 10.3%) and only three subjects (7%) faced a drop below the upper normal limit of 53%. However, when patients were categorized by median LV-SUV, LVEF at ECHO POST  resulted significantly lower in those with LV-SUV above than below the median value at both PET INTERIM  (65.5 ± 11.8% vs. 71.9 ± 7.8%,  P  = 0.04) and PET EOT  (65.6 ± 12.2% vs. 72.2 ± 7.0%,  P  = 0.04). This was also the case when only patients with ECHO PRE  and ECHO POST  were considered (LVEF at ECHO POST  64.7 ± 8.9% vs. 73.4 ± 7.6%,  P  = 0.01 and 64.6 ± 9.3% vs. 73.5 ± 7.0%,  P  = 0.01 for those with LV-SUV above vs. below the median at PET INTERIM  and PET EOT , respectively). Furthermore, the difference between LVEF at ECHO PRE  and ECHO POST  was inversely correlated with LV-SUV at PET EOT  ( P  < 0.01, R 2  = − 0.30).    Conclusions  DOX-containing chemotherapy causes an increase in cardiac  18 FDG uptake, which is associated with a decline in LVEF. Future studies are warranted to understand the molecular basis and the potential clinical implications of this observation.

journal of translational medicine

An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline